NRX Pharmaceuticals Inc. Common Stock (NRXP)
Stock · NASDAQ · Health Care
$2.6as of 10/16/2026
Price chart
Active signals
NRXP Signal Track Record
How signals performed across all stocks →What NRXP's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | -1.0% | 44% | September 14, 2026 |
| Bollinger Band Breakout | 24 | -0.5% | 50% | July 15, 2026 |
| Bollinger Band Breakdown | 22 | -10.4% | 23% | September 23, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +1.5% | 56% | September 29, 2026 |
| Any 20-session window (baseline) | -3.4% | 45% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About NRXP
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinica…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 29
- Website
- www.nrxpharma.com/
Fundamentals
- 1-day range
- $2.48$2.77
- Market cap
- $111.95M
- P/E (trailing)
- —
- P/E (forward)
- -7.74
- EPS (trailing)
- $-0.74
- Dividend yield
- —
- Beta
- 2.02
- Avg. volume
- 848.0K
How NRX Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 23, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
NRX Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- NRXPNRX Pharmaceuticals Inc. Common Stock$2.6▼ 4.06%Market cap $111.95MP/E —$1.62$5.06
- PLYXPolaryx Therapeutics Inc. Common Stock$1.88▼ 3.59%Market cap $110.66MP/E —$1.85$48.91
- CUECue Biopharma Inc. Common Stock$16.71▼ 10.50%Market cap $113.45MP/E —$4.97$45.5
- CPIXCumberland Pharmaceuticals Inc. Common Stock$7.18▼ 4.77%Market cap $115.07MP/E —$1.85$9.28
- COYACoya Therapeutics Inc. Common Stock$4.25▼ 2.07%Market cap $107.43MP/E —$3.71$7.75
- ANIXAnixa Biosciences Inc. Common Stock$2.67▼ 3.96%Market cap $116.70MP/E —$2.32$5.46
- YARWYarrow Bioscience Inc. Common Stock$18.31▼ 8.45%Market cap $116.71MP/E —$18.16$44.28
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| NRXP NRX Pharmaceuticals Inc. Common Stock | $111.95M | — | $2.6 | ▼ 4.06% | $1.62$5.06 |
| PLYX Polaryx Therapeutics Inc. Common Stock | $110.66M | — | $1.88 | ▼ 3.59% | $1.85$48.91 |
| CUE Cue Biopharma Inc. Common Stock | $113.45M | — | $16.71 | ▼ 10.50% | $4.97$45.5 |
| CPIX Cumberland Pharmaceuticals Inc. Common Stock | $115.07M | — | $7.18 | ▼ 4.77% | $1.85$9.28 |
| COYA Coya Therapeutics Inc. Common Stock | $107.43M | — | $4.25 | ▼ 2.07% | $3.71$7.75 |
| ANIX Anixa Biosciences Inc. Common Stock | $116.70M | — | $2.67 | ▼ 3.96% | $2.32$5.46 |
| YARW Yarrow Bioscience Inc. Common Stock | $116.71M | — | $18.31 | ▼ 8.45% | $18.16$44.28 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- NRx Pharmaceuticals Announces FDA Receipt Of DISCIPLINE REVIEW LETTER For Changes To Submitted Label For Preservative-Free Ketamine Product Ahead Of Nov. 10benzinga · 10/15/2026
- Ascendiant Capital Maintains Buy on NRX Pharmaceuticals, Raises Price Target to $50Benzinga · 10/1/2026
- NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant DepressionYahoo · 9/30/2026
- NRx Pharma’s NRx Defense Systems Announces Award Of Initial $11M Contract Issued By Defense Advanced Research Projects AgencyBenzinga · 9/30/2026
- Ono Pharmaceutical Co. (OPHLF) Soars 13.9%: Is Further Upside Left in the Stock?Yahoo · 9/24/2026
- NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free KetamineYahoo · 9/15/2026
- FDA Reclassifies NRx Pharmaceuticals' Ketamine ANDA Amendment To Minor, Setting New Goal Date For November 10, 2026Benzinga · 9/15/2026
- BTIG Reiterates Buy on NRX Pharmaceuticals, Maintains $10 Price TargetBenzinga · 9/14/2026
- GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)Yahoo · 9/14/2026
Institutional Ownership
March 31, 2026
- Total shares held
- 6.26M
- Total value held
- $13.29M
- Institutional holders
- 32
- Unknown3.00M
- Unknown1.16M
- Unknown420.5K
- Unknown397.4K
- Unknown310.1K
- Unknown180.7K
- Unknown117.2K
- Unknown102.2K
- Unknown99.0K
- Unknown87.0K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Ono Pharmaceutical Rallies 13.9% Amid NRX Partnership
Ono Pharmaceutical shares rose 13.9%, a move likely tied to its ongoing relationship with NRX Pharmaceuticals. This partner's stock performance often influences sentiment around NRX, which is currently trading near its 52-week low. The significant gain in the partner's stock highlights the continued relevance of their collaboration in the market.
Ono Pharmaceutical Rallies 13.9% Amid NRX Partnership. Ono Pharmaceutical shares rose 13.9%, a move likely tied to its ongoing relationship with NRX Pharmaceuticals. This partner's stock performance often influences sentiment around NRX, which is currently trading near its 52-week low. The significant gain in the partner's stock highlights the continued relevance of their collaboration in the market.